Chemotherapy of non-small cell lung cancer: a reappraisal and a look to the future

Cancer Treatment Reviews

Volumn 10, Issue 3, 1983, Pages 159-172

  Bakowski, Marie T ^a   Crouch, Jennifer C ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CHLORMETHINE; CHLOROZOTOCIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DIANHYDROGALACTITOL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; IFOSFAMIDE; LOMUSTINE; MAYTANSINE; MELPHALAN; METHENAMINE; METHOTREXATE; MITOGUAZONE; MITOLACTOL; MITOMYCIN; PIRAZOFURIN; PROCARBAZINE; RAZOXANE; SEMUSTINE; TEGAFUR; TENIPOSIDE; TRIAZINATE; VINBLASTINE; VINCRISTINE; VINDESINE; ZORUBICIN;

2,5 PIPERAZINEDIONE; ADENOCARCINOMA; ANAPLASTIC CARCINOMA; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; HUMAN; LUNG CARCINOMA; RESPIRATORY SYSTEM; SHORT SURVEY; SQUAMOUS CELL CARCINOMA; THERAPY;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SMALL CELL; CARCINOMA, SQUAMOUS CELL; CISPLATIN; CLINICAL TRIALS; CYCLOPHOSPHAMIDE; DIANHYDROGALACTITOL; DOXORUBICIN; HUMAN; IFOSFAMIDE; LUNG NEOPLASMS; MITOMYCIN; MITOMYCINS; RANDOM ALLOCATION; VINBLASTINE; VINDESINE;

EID: 0021088681     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/0305-7372(83)90030-0     Document Type: Article

References (80)

1. Etoposide-an effective single drug for treating bronchogenic carcinoma
2. Therapy of advanced squamous carcinoma of the lung: Cyclophosphamide verses “COMB”
3. Chemotherapy of lung cancer: The experience of the National Cancer Institute of Milan
4. Cis-dichlorodiammineplatinum (II) alone followed by adriamycin plus cyclophosphamide at progression versus cis-dichlorodiammine-platinum (II), adriamycin, and cyclophosphamide in combination for adenocarcinoma of the lung
5. Clinical study of vincristine in adenocarcinoma of the lung
6. Vincristine (NSC 67574) in non-small cell bronchogenic carcinoma
7. 5-Fluorouracil (NSC-19893) compared to cyclophosphamide (NSC-26271) in bronchogenic carcinoma: Results of a clinical study
8. Phase II evaluation of chlorozotocin in patients with non-small cell carcinoma of the lung
9. Phase II study of high-dose cis-dichlorodiammineplatinum (II) in the treatment of non-small cell lung cancer
10. Phase II evaluation of N-(phosphonacetyl)-L-aspartic acid (PALA) in patients with non-small cell carcinoma of the lung
11. Phase II evaluation of 4′-(9-acridinylamino)-methanesulfon-m-anisidide (AMSA) in patients with non-small cell lung cancer
12. Phase II trial of VP-16-213 in non-small cell lung cancer
13. Benefits of polychemotherapy in advanced non-small-cell bronchogenic carcinoma
14. Phase II study of chlorozotocin in non-small cell carcinoma of the lung
15. Adriamycin in advanced bronchogenic carcinoma
16. Ifosfamide in the treatment of recurrent or disseminated lung cancer
17. Ifosfamide in the treatment of extensive non-oat cell carcinoma of the lung
18. Phase II evaluation of triazinate in patients with metastatic lung cancer
19. Phase II evaluation of chlorozotocin in advanced bronchogenic carcinoma
20. Phase II evaluation of PALA in patients with metastatic lung cancer
21. Results of a phase II protocol for evaluation of new chemotherapeutic regimens in patients with inoperable non-small cell lung carcinoma (EST-2575 Generation I)
22. Single-agent and combination chemotherapy for extensive non-small cell carcinomas of the lung
23. High dose cisplatin with fluid and mannitol-induced diuresis in advanced lung cancer: A phase II trial of the EORTC lung cancer working party
24. Hexamethylmelamine (NSC-13875) in the treatment of primary cancer of the lung with metastasis
25. Comparison of treatment policies in inoperable bronchial carcinoma
26. Randomised study comparing CCNU (NSC-79037) and methyl-CCNU (NSC-95441) in advanced bronchogenic carcinoma
27. ICRF-159 versus polychemotherapy in non-small cell lung cancer
28. Phase II evaluation of maytansine in patients with metastatic lung cancer
29. Evaluation of an intermittent schedule of mitolactol in advanced non-small cell lung cancer
30. VP-16-213 chemotherapy for advanced squamous cell carcinoma and adenocarcinoma of the lung
31. Platinum-based polychemotherapy versus dianhydrogalactitol in advanced non-small cell lung cancer
32. Cyclophosphamide and CCNU in the treatment of inoperable small cell and adenocarcinoma of the lung
33. Mechlorethamine (NSC-762) plus CCNU (NSC-79037) in the treatnent of inoperable squamous and large cell carcinoma of the lung
34. Randomized comparison of vindesine (VDS) versus vindesine plus cis-platinum (DDP) in inoperable non-small cell lung cancer (NSCLC)
35. Phase II study of high-dose methotrexate in the treatment of patients with non-small cell carcinoma of the lung: An Eastern Cooperative Oncology Group Study
36. Vindesine: An effective agent in the treatment of non-small cell lung cancer
37. Clinical trial of rubidazone in advanced squamous cell carcinoma of the lung and adenocarcinoma of the large intestine
38. Phase II evaluation of pyrazofurin in patients with carcinoma of the lung
39. Phase II evaluation of vindesine in patients with non-small cell carcinoma of the lung
40. Phase II evaluation of bleomycin
41. Single-dose ifosfamide: Efficacy studies in non-small cell lung cancer
42. CCNU (1-[2-chloroethyl]-3-cylohexyl-1-nitrosourea, (NSC-79037) in the treatment of cancer
43. CCNU and bleomycin in the treatment of cancer: SWOG study
44. Results of a clinical trial with intermittent doses of adriamycin in lung cancer
45. Phase II studies of methyl glyoxal bis-guanylhydrazone (NSC-32946) in carcinoma of the colon and lung
46. Mitomycin C
47. Adriamycin in the treatment of far-advanced lung cancer
48. Treatment of inoperable carcinoma of bronchus
49. A randomised prospective study of vindesine versus doxorubicin and cyclophosphamide in the treatment of epidermoid lung cancer
50. Vindesine (VDS) monochemotherapy for non-small cell lung cancer: A report of 45 cases
51. Ifosfamide: A weekly dose fractionated schedule in bronchogenic carcinoma
52. Vindesine in the treatment of small cell and non-small cell bronchogenic carcinoma: preliminary results
53. Phase II evaluation of AMSA in patients with metastatic lung cancer
54. Clinical trial of VP16-213 (NSC 141540) iv twice weekly in advanced neoplastic disease
55. Phase II evaluation of adriamycin in human neoplasia
56. Vindesine in the treatment of squamous cell carcinoma, adenocarcinoma, and large cell carcinoma of the lung
57. Phase 2 study with Baker's antifol in solid tumours
58. Phase II evaluation of cis-diamminedichloroplatinum (II) in lung cancer
59. Chemotherapy for inoperable, non-small cell bronchogenic carcinoma: EST 2575, Generation II
60. Randomised phase II comparison of methotrexate with or without L-asparaginase in non-small cell cancer of the lung
61. Phase II clinical studies of vindesine and combination of ifosfamide and acetylcysteine in non-small cell lung cancer
62. VM26 (NSC-122819): A clinical study in advanced cancer of the lung and ovary
63. Mitomycin C in advanced adenocarcinoma and large cell carcinoma of the lung
64. Phase II study of AMSA in lung cancer
65. Procarbazine (NSC-77213) in the treatment of advanced bronchogenic carcinoma
66. Phase II study of divided-dose vinblastine in non-small cell bronchogenic carcinoma
67. Methotrexate compared with placebo in lung cancer
68. Methotrexate in the chemotherapy of lung cancer
69. Response to vindesine or vincristine in inoperable non-small cell carcinoma of the bronchus
70. Trial of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU; NSC-79037) in advanced bronchogenic carcinoma
71. Hexamethylmelamine in inoperable bronchogenic carcinoma
72. Effect of CCNU (NSC-79037) on bronchogenic carcinoma.
73. Intermittent high-dose cyclophosphamide with and without prednisolone
74. Oral high-dose methotrexate with citrovorum factor rescue in metastatic squamous cell carcinoma of the lung
75. Evaluation of methotrexate in the treatment of bronchogenic carcinoma
76. Vindesine in bronchogenic carcinoma
77. Efficacy study of intensive cis-platin therapy in advanced non-small cell bronchogenic carcinoma
78. Clinical experience with mitomycin C (NSC-26980)
79. A phase III study in lung carcinoma comparing hexamethylmelamine (NSC-13875) to dibromodulcitol (NSC-104800)
80. Recent comparative trials of systemic therapy in non-small cell carcinoma of the lung